Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01633099
Recruitment Status : Unknown
Verified July 2012 by Jianxiang Wang, Chinese Academy of Medical Sciences.
Recruitment status was:  Active, not recruiting
First Posted : July 4, 2012
Last Update Posted : July 6, 2012
Sponsor:
Collaborator:
Xian-Janssen Pharmaceutical Ltd.
Information provided by (Responsible Party):
Jianxiang Wang, Chinese Academy of Medical Sciences

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to confirm the safety and the therapeutic effect of Decitabine in the treatment of elderly Acute Myeloid Leukemia (AML) patients.

Condition or disease Intervention/treatment Phase
Untreated Adult Acute Myeloid Leukemia Effect of Drugs Drug Safety Drug: Decitabine Phase 3

Detailed Description:
The outcome of the elderly AML patients is very poor. No obvious progress was achieved in this field. Decitabine is a kind of specific DNA methylation shift enzyme inhibitor. It can reverse the DNA methylation and induce the differentiation and apoptosis of the tumor cells. Recent studies about decitabine in the treatment for elderly AML patients had achieved inspiring results and indicated that low dose decitabine maybe a good choice for elderly AML patients. So in this research the investigators plan to evaluate the safety and the therapeutic effect of decitabine in the treatment of elderly AML patients.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients
Study Start Date : May 2012
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Decitabine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Decitabine, CR rate,OS,EFS,RFS
Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
 Drug: Decitabine
  1. Number of Cycles: 4 cycles.
  2. Dose and drug delivery(decitabine):

The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.

If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.

If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle).

Other Name: Dacogen


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Complete response rate after induction chemotherapy with decitabine [ Time Frame: 21 days after the induction chemotherapy ]
  2. Overall survival rate [ Time Frame: Up to 46 months after inclusion ]
  3. Event free survival rate [ Time Frame: Up to 46 months after inclusion ]
  4. Relapse free survival rate [ Time Frame: Up to 46 months after inclusion ]

Secondary Outcome Measures :
  1. Adverse events of decitabine for elderly AML patients [ Time Frame: Up to 46 months ]
  2. Weight of elderly AML patients [ Time Frame: Up to 46 months ]
  3. ECOG(Eastern Cooperative Oncology Group) score for elderly AML patients [ Time Frame: Up to 46 months ]
  4. Physical examination of decitabine for elderly AML patients [ Time Frame: Up to 46 months ]
  5. Blood pressure of elderly AML patients [ Time Frame: Up to 46 months ]
  6. Respiratory rate of elderly AML patients [ Time Frame: Up to 46 months ]
  7. Heart rate of elderly AML patients [ Time Frame: Up to 46 months ]
  8. Body temperature of elderly AML patients [ Time Frame: Up to 46 months ]
  9. ECG of elderly AML patients [ Time Frame: Up to 46 months ]
  10. Bone marrow condition of elderly AML patients [ Time Frame: Up to 46 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical diagnosis of acute myeloid leukemia.De novo or secondary AML.
  2. Age >= 60years,female and male.
  3. Before the enrollment，WBC < 40×10E9/L，Plt > 20×10E9/L（Hydroxyurea is permitted.）
  4. In 2 weeks before the enrollment，total bilirubin < 1.5×ULN，ALT < 2.5×ULN；GGT < 2.5×ULN ，Scr < 2.0×ULN or creatinine clearance rate ≥ 50 ml/min（Cockroft-Gault）.
  5. Before the enrollment，patients must be free from the toxicity caused by the former treatment.Received no chemotherapy in the last 4 weeks and no nitrosourea in the last 6 weeks.
  6. Contraception must be taken to avoid pregnancy during the study.
  7. ECOG 0,1, or 2, predicted lifetime longer than 12 weeks.
  8. Patients must sign the informed consent prior to any study related screening procedures being performed.

Exclusion Criteria:

  1. Acute promyelocytic leukemia.
  2. Chromosome and genetic abnormalities related with t（8; 21）、inv（16）、t（15; 17）.
  3. Central nervous system leukemia.
  4. Bone marrow dry tap.
  5. Patients received stem cell transplantation or chemotherapy containing azacitidine,cytarabine or decitabine in last one year, radiation therapy in last 14 days,lenalidomide in 30 days before included.
  6. Patients suffered from autoimmune hemolytic anemia or immune thrombocytopenia.
  7. Patients suffered from non-leukemia related comorbidities that will cause dysfunction of organs.
  8. Patients suffered from unstable angina or （NYHA）3/4 Congestive heart failure.
  9. Patients suffered from chronic respiratory disease and needed continued oxygen.
  10. Other active malignancy.
  11. Active HBV,HCV or AIDS patients.
  12. Uncontrolled virus or bacterium infection.
  13. The investigator believe that patients who are not suitable for this trial.
  14. Severe mental or body disorders which will interfere the research such as uncontrolled heart,lung diseases,diabetes,etc.
  15. Allergic to decitabine or its accessory.
  16. Patients received other researches in last 30 days.
  17. Without contraception.
  18. Complications causing organ dysfunction which are not caused by AML.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01633099


Sponsors and Collaborators
Jianxiang Wang
Xian-Janssen Pharmaceutical Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jianxiang Wang, MD Institute of Hematology, Hospital of Blood Disease, Chinese Academy of Medical Sciences
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
We do not have a protocol's home page. This website is our hospital's home page and introduces some information of our hospital.  This link exits the ClinicalTrials.gov site

Publications:

Layout table for additonal information
Responsible Party: Jianxiang Wang, deputy director, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT01633099     History of Changes
Other Study ID Numbers: DACOGENAML2003
First Posted: July 4, 2012    Key Record Dates
Last Update Posted: July 6, 2012
Last Verified: July 2012

Keywords provided by Jianxiang Wang, Chinese Academy of Medical Sciences:
decitabine
acute myeloid leukemia
elderly patient

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Decitabine
 Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors